# Geographic Variation in Opioid Mortality by Race/Ethnicity, 1999–2016

Identifying epidemic hotspots

Mathew Kiang<sup>1</sup> Monica Alexander<sup>2</sup> Zhe Zhang<sup>3</sup> Jarvis Chen<sup>1</sup>


<sup>1</sup>Deptartment of Social and Behavioral Sciences Harvard TH Chan School of Public Health

<sup>2</sup>Department of Demography University of California, Berkeley


<sup>3</sup>Heinz College Carnegie Mellon University

PAA 2018: Denver, CO

#### Almost 30x increase since 1980




## More than deaths by car accidents or guns




Variation in the opioid epidemic


#### Variation by opioid type



## Variation by race/ethnicity



#### Variation by state



## Aims of the paper

- Systematically describe the opioid epidemic across geography (state), race/ethnicity, and opioid type.
  - The epidemic over time (1999–2016)
  - The current epidemic in terms of both mortality rate and rate of increase

## Aims of the paper

- Systematically describe the opioid epidemic across geography (state), race/ethnicity, and opioid type.
  - The epidemic over time (1999-2016)
  - The *current* epidemic in terms of both mortality rate and rate of increase
- Identify "epidemic hotspots" areas with high mortality and rapid increases

## Data / Methods

• Multiple cause of death data from NCHS


#### Data / Methods

- Multiple cause of death data from NCHS
- Calculate age-standardized rates by state, race/ethnicity, and opioid type


#### Data / Methods

- Multiple cause of death data from NCHS
- Calculate age-standardized rates by state, race/ethnicity, and opioid type
- Joinpoint regression

## **Example Results: Maryland**




## **Example Results: Synthetic Opioids**




**Results: Current Epidemic** 

## **Current Mortality**




Mortality (per 100,000) [0.2.5] (2.5.5] (5.7.5] (7.5.10] (10.15] (15.20] (20.25] (25.34] NA

#### **Current Trajectory**



APC (%) /0 E1 /5 401 /10 151 /15 201 /20 301 /30 501 /50 751 /75 1001 /100 3311 NA

#### **Epidemic Hotspots**





• No decreases in opioid mortality over whole time period

- No decreases in opioid mortality over whole time period
- Where there were increases, it is just as bad (or worse) for the black population

- No decreases in opioid mortality over whole time period
- Where there were increases, it is just as bad (or worse) for the black population
- Increases are driven by heroin and synthetic opioids in eastern states
  - Heroin deaths increased 30-34% per year for both populations
  - $\bullet$  Synthetic opioids increased 70% per year for whites and 150% for blacks

- No decreases in opioid mortality over whole time period
- Where there were increases, it is just as bad (or worse) for the black population
- Increases are driven by heroin and synthetic opioids in eastern states
  - Heroin deaths increased 30-34% per year for both populations
  - $\bullet$  Synthetic opioids increased 70% per year for whites and 150% for blacks
- Synthetic opioids are doubling in 12 states for whites and 18 for blacks

- No decreases in opioid mortality over whole time period
- Where there were increases, it is just as bad (or worse) for the black population
- Increases are driven by heroin and synthetic opioids in eastern states
  - Heroin deaths increased 30-34% per year for both populations
  - $\bullet$  Synthetic opioids increased 70% per year for whites and 150% for blacks
- Synthetic opioids are doubling in 12 states for whites and 18 for blacks
- Strong geographical clustering of epidemic hotspots

#### **Conclusions**

 Interventions must be local and tailored to region, race/ethnicity, and opioid type

#### **Conclusions**

- Interventions must be local and tailored to region, race/ethnicity, and opioid type
- Supply-side interventions need to be balanced with harm reduction interventions
  - Syringe exchange programs
  - Medication assisted treatment
  - Increased naloxone access
  - Drug testing on-site and point-of-site
  - Supervised consumption sites

#### **Conclusions**

- Interventions must be local and tailored to region, race/ethnicity, and opioid type
- Supply-side interventions need to be balanced with harm reduction interventions
  - Syringe exchange programs
  - Medication assisted treatment
  - Increased naloxone access
  - Drug testing on-site and point-of-site
  - Supervised consumption sites
- Surveillance of illicit markets needs to be dramatically improved
  - Better measurement of potency of drugs
  - Types of drugs
  - Cost and availability


#### Thank you

## Code and interactive results explorer:

https://tiny.cc/paa2018

mathewkiang.com | **○**: mkiang | **>**: @mathewkiang

#### **Epidemic Hotspots**



## **Average Annual Percent Change**

